{"pmid":32353857,"title":"Do we know the diagnostic properties of the tests used in COVID-19? A rapid review of recently published literature.","text":["Do we know the diagnostic properties of the tests used in COVID-19? A rapid review of recently published literature.","COVID-19 has brought death and disease to large parts of the world. Governments must deploy strategies to screen the population and subsequently isolate the suspect cases. Diagnostic testing is critical for epidemiological surveillance, but the accuracy (sensitivity and specificity) and clinical utility (impact on health outcomes) of the current diagnostic methods used for SARS-CoV-2 detection are not known. I ran a quick search in PubMed/MEDLINE to find studies on laboratory diagnostic tests and rapid viral diagnosis. After running the search strategies, I found 47 eligible articles that I discuss in this review, commenting on test characteristics and limitations. I did not find any papers that report on the clinical utility of the tests currently used for COVID-19 detection, meaning that we are fighting a battle without proper knowledge of the proportion of false negatives that current testing is resulting in. This shortcoming should not be overlooked as it might hamper national efforts to contain the pandemic through testing community-based suspect cases.","Medwave","Bachelet, Vivienne C","32353857"],"abstract":["COVID-19 has brought death and disease to large parts of the world. Governments must deploy strategies to screen the population and subsequently isolate the suspect cases. Diagnostic testing is critical for epidemiological surveillance, but the accuracy (sensitivity and specificity) and clinical utility (impact on health outcomes) of the current diagnostic methods used for SARS-CoV-2 detection are not known. I ran a quick search in PubMed/MEDLINE to find studies on laboratory diagnostic tests and rapid viral diagnosis. After running the search strategies, I found 47 eligible articles that I discuss in this review, commenting on test characteristics and limitations. I did not find any papers that report on the clinical utility of the tests currently used for COVID-19 detection, meaning that we are fighting a battle without proper knowledge of the proportion of false negatives that current testing is resulting in. This shortcoming should not be overlooked as it might hamper national efforts to contain the pandemic through testing community-based suspect cases."],"journal":"Medwave","authors":["Bachelet, Vivienne C"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32353857","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.5867/medwave.2020.03.7891","keywords":["diagnosis","sars-cov-2","testing","covid-19"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495699124224,"score":9.490897,"similar":[{"pmid":32342570,"title":"An Overview of COVID-19 Testing and Implications for Otolaryngologists.","text":["An Overview of COVID-19 Testing and Implications for Otolaryngologists.","BACKGROUND: Testing for SARS-CoV-2 is important for decision making prior to surgery in otolaryngology. An understanding of current and developing testing methods is important for interpreting test results. METHODS: We performed a literature review of current evidence surrounding SARS-CoV-2 diagnostic testing highlighting its utility, limitations, and implications for otolaryngologists. RESULTS: The currently accepted RT-PCR test for SARS-CoV-2 has varying sensitivity according to which subsite of the aerodigestive tract is sampled. Nasal swab sensitivities appear to be about 70%. Chest CT imaging for screening purposes is not currently recommended. CONCLUSION: Due to the current sensitivity of RT-PCR based testing for SARS-CoV-2, a negative test cannot rule out COVID-19. Full PPE should be worn during high risk procedures such as aerosol generating procedures even if testing is negative. Patients who test positive during screening should have their surgeries postponed if possible until asymptomatic and have tested negative for SARS-CoV-2.","Head Neck","Vinh, Daniel B","Zhao, Xiao","Kiong, Kimberley L","Guo, Theresa","Jozaghi, Yelda","Yao, Chris","Kelley, James M","Hanna, Ehab","32342570"],"abstract":["BACKGROUND: Testing for SARS-CoV-2 is important for decision making prior to surgery in otolaryngology. An understanding of current and developing testing methods is important for interpreting test results. METHODS: We performed a literature review of current evidence surrounding SARS-CoV-2 diagnostic testing highlighting its utility, limitations, and implications for otolaryngologists. RESULTS: The currently accepted RT-PCR test for SARS-CoV-2 has varying sensitivity according to which subsite of the aerodigestive tract is sampled. Nasal swab sensitivities appear to be about 70%. Chest CT imaging for screening purposes is not currently recommended. CONCLUSION: Due to the current sensitivity of RT-PCR based testing for SARS-CoV-2, a negative test cannot rule out COVID-19. Full PPE should be worn during high risk procedures such as aerosol generating procedures even if testing is negative. Patients who test positive during screening should have their surgeries postponed if possible until asymptomatic and have tested negative for SARS-CoV-2."],"journal":"Head Neck","authors":["Vinh, Daniel B","Zhao, Xiao","Kiong, Kimberley L","Guo, Theresa","Jozaghi, Yelda","Yao, Chris","Kelley, James M","Hanna, Ehab"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32342570","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/hed.26213","keywords":["covid-19","pcr","sars-cov-2","sensitivity","testing"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495854313474,"score":190.7057},{"pmid":32497809,"title":"Evaluation of novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples.","text":["Evaluation of novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples.","OBJECTIVES: In the context of the Covid-19 pandemic, the development and validation of rapid and easy-to-perform diagnostic methods are of high priority. We evaluated a novel rapid antigen detection test (RDT) for SARS-CoV-2 in respiratory samples. METHODS: The fluorescence immunochromatographic SARS-CoV-2 antigen test (Bioeasy Biotechnology Co., Shenzhen, China) was evaluated using universal transport medium with nasopharyngeal (NP) and oropharyngeal (OP) swabs from suspected Covid-19 cases. Diagnostic accuracy was determined in comparison to SARS-CoV-2 real time (RT)-PCR. RESULTS: A total of 127 samples were included; 82 were RT-PCR positive. Median patients' age was 38 years, 53.5% were male, and 93.7% were from the first week after symptom onset. Overall sensitivity and specificity were 93.9% (CI95% 86.5-97.4) and 100% (CI95% 92.1-100), respectively, with a diagnostic accuracy of 96.1% and Kappa coefficient of 0.9. Sensitivity was significantly higher in samples with high viral loads. CONCLUSIONS: The evaluated RDT showed a high sensitivity and specificity in samples mainly obtained during the first week of symptoms and with high viral loads, despite the use of a non-validated sample material. The assay has the potential to become an important tool for early diagnosis of SARS-CoV-2, particularly in situations with limited access to molecular methods.","Int J Infect Dis","Porte, Lorena","Legarraga, Paulette","Vollrath, Valeska","Aguilera, Ximena","Munita, Jose M","Araos, Rafael","Pizarro, Gabriel","Vial, Pablo","Iruretagoyena, Mirentxu","Dittrich, Sabine","Weitzel, Thomas","32497809"],"abstract":["OBJECTIVES: In the context of the Covid-19 pandemic, the development and validation of rapid and easy-to-perform diagnostic methods are of high priority. We evaluated a novel rapid antigen detection test (RDT) for SARS-CoV-2 in respiratory samples. METHODS: The fluorescence immunochromatographic SARS-CoV-2 antigen test (Bioeasy Biotechnology Co., Shenzhen, China) was evaluated using universal transport medium with nasopharyngeal (NP) and oropharyngeal (OP) swabs from suspected Covid-19 cases. Diagnostic accuracy was determined in comparison to SARS-CoV-2 real time (RT)-PCR. RESULTS: A total of 127 samples were included; 82 were RT-PCR positive. Median patients' age was 38 years, 53.5% were male, and 93.7% were from the first week after symptom onset. Overall sensitivity and specificity were 93.9% (CI95% 86.5-97.4) and 100% (CI95% 92.1-100), respectively, with a diagnostic accuracy of 96.1% and Kappa coefficient of 0.9. Sensitivity was significantly higher in samples with high viral loads. CONCLUSIONS: The evaluated RDT showed a high sensitivity and specificity in samples mainly obtained during the first week of symptoms and with high viral loads, despite the use of a non-validated sample material. The assay has the potential to become an important tool for early diagnosis of SARS-CoV-2, particularly in situations with limited access to molecular methods."],"journal":"Int J Infect Dis","authors":["Porte, Lorena","Legarraga, Paulette","Vollrath, Valeska","Aguilera, Ximena","Munita, Jose M","Araos, Rafael","Pizarro, Gabriel","Vial, Pablo","Iruretagoyena, Mirentxu","Dittrich, Sabine","Weitzel, Thomas"],"date":"2020-06-05T11:00:00Z","year":2020,"_id":"32497809","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.ijid.2020.05.098","keywords":["coronavirus","covid-19","sars-cov-2","antigen","diagnosis","rapid diagnostic test"],"locations":["Shenzhen","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1668712823866261504,"score":184.29915},{"pmid":32330437,"pmcid":"PMC7165277","title":"COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil.","text":["COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil.","The accuracy of commercially available tests for COVID-19 in Brazil remains unclear. We aimed to perform a meta-analysis to describe the accuracy of available tests to detect COVID-19 in Brazil. We searched at the Brazilian Health Regulatory Agency (ANVISA) online platform to describe the pooled sensitivity (Se), specificity (Sp), diagnostic odds ratio (DOR) and summary receiver operating characteristic curves (SROC) for detection of IgM/IgG antibodies and for tests using naso/oropharyngeal swabs in the random-effects models. We identified 16 tests registered, mostly rapid-tests. Pooled diagnostic accuracy measures [95%CI] were: (i) for IgM antibodies Se=82% [76-87]; Sp=97% [96-98]; DOR=168 [92-305] and SROC=0.98 [0.96-0.99]; (ii) for IgG antibodies Se=97% [90-99]; Sp=98% [97-99]; DOR=1994 [385-10334] and SROC=0.99 [0.98-1.00]; and (iii) for detection of SARS-CoV-2 by antigen or molecular assays in naso/oropharyngeal swabs Se=97% [85-99]; Sp=99% [77-100]; DOR=2649 [30-233056] and SROC=0.99 [0.98-1.00]. These tests can be helpful for emergency testing during the COVID-19 pandemic in Brazil. However, it is important to highlight the high rate of false negative results from tests which detect SARS-CoV-2 IgM antibodies in the initial course of the disease and the scarce evidence-based validation results published in Brazil. Future studies addressing the diagnostic performance of tests for COVID-19 in the Brazilian population are urgently needed.","Braz J Infect Dis","Castro, Rodolfo","Luz, Paula M","Wakimoto, Mayumi D","Veloso, Valdilea G","Grinsztejn, Beatriz","Perazzo, Hugo","32330437"],"abstract":["The accuracy of commercially available tests for COVID-19 in Brazil remains unclear. We aimed to perform a meta-analysis to describe the accuracy of available tests to detect COVID-19 in Brazil. We searched at the Brazilian Health Regulatory Agency (ANVISA) online platform to describe the pooled sensitivity (Se), specificity (Sp), diagnostic odds ratio (DOR) and summary receiver operating characteristic curves (SROC) for detection of IgM/IgG antibodies and for tests using naso/oropharyngeal swabs in the random-effects models. We identified 16 tests registered, mostly rapid-tests. Pooled diagnostic accuracy measures [95%CI] were: (i) for IgM antibodies Se=82% [76-87]; Sp=97% [96-98]; DOR=168 [92-305] and SROC=0.98 [0.96-0.99]; (ii) for IgG antibodies Se=97% [90-99]; Sp=98% [97-99]; DOR=1994 [385-10334] and SROC=0.99 [0.98-1.00]; and (iii) for detection of SARS-CoV-2 by antigen or molecular assays in naso/oropharyngeal swabs Se=97% [85-99]; Sp=99% [77-100]; DOR=2649 [30-233056] and SROC=0.99 [0.98-1.00]. These tests can be helpful for emergency testing during the COVID-19 pandemic in Brazil. However, it is important to highlight the high rate of false negative results from tests which detect SARS-CoV-2 IgM antibodies in the initial course of the disease and the scarce evidence-based validation results published in Brazil. Future studies addressing the diagnostic performance of tests for COVID-19 in the Brazilian population are urgently needed."],"journal":"Braz J Infect Dis","authors":["Castro, Rodolfo","Luz, Paula M","Wakimoto, Mayumi D","Veloso, Valdilea G","Grinsztejn, Beatriz","Perazzo, Hugo"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330437","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.bjid.2020.04.003","keywords":["coronavirus","diagnostic accuracy","sars-cov-2"],"locations":["Brazil","Brazil","Brazil","Brazil","Brazilian","Brazil"],"countries":["Brazil"],"countries_codes":["BRA|Brazil"],"topics":["Diagnosis"],"weight":1,"_version_":1666138494712414209,"score":182.91829},{"pmid":32462770,"title":"The Diagnosis of SARS-CoV2 Pneumonia: A Review of Laboratory and Radiological Testing Results.","text":["The Diagnosis of SARS-CoV2 Pneumonia: A Review of Laboratory and Radiological Testing Results.","The rapid emergence of COVID-19 (coronavirus disease 2019) has necessitated the implementation of diverse pandemic control strategies throughout the world. In order to effectively control the spread of this disease, it is essential that it be diagnosed at an early stage so that patients can be reliably quarantined such that disease spread will be slowed. At present, the diagnosis of this infectious form of coronavirus pneumonia is largely dependent upon a combination of laboratory testing and imaging analyses of variable diagnostic efficacy. In the present report, we reviewed prior literature pertaining to the diagnosis of different forms of pneumonia caused by coronaviruses (SARS, MERS, and SARS-CoV-2) and assessed two different potential diagnostic approaches. We ultimately found that computed tomography (CT) was associated with a higher rate of diagnostic accuracy than was a real-time quantitative polymerase chain reaction (qPCR)-based approach (P = 0.0041), and chest radiography (P = 0.0100). Even so, it is important that clinicians utilize a combination of laboratory and radiological testing where possible in order to ensure that this virus is reliably and quickly detected such that it may be treated and patients may be isolated in a timely fashion, thereby effectively curbing the further progression of this pandemic. This article is protected by copyright. All rights reserved.","J Med Virol","Zheng, Zhong","Yao, Zhixian","Wu, Ke","Zheng, Junhua","32462770"],"abstract":["The rapid emergence of COVID-19 (coronavirus disease 2019) has necessitated the implementation of diverse pandemic control strategies throughout the world. In order to effectively control the spread of this disease, it is essential that it be diagnosed at an early stage so that patients can be reliably quarantined such that disease spread will be slowed. At present, the diagnosis of this infectious form of coronavirus pneumonia is largely dependent upon a combination of laboratory testing and imaging analyses of variable diagnostic efficacy. In the present report, we reviewed prior literature pertaining to the diagnosis of different forms of pneumonia caused by coronaviruses (SARS, MERS, and SARS-CoV-2) and assessed two different potential diagnostic approaches. We ultimately found that computed tomography (CT) was associated with a higher rate of diagnostic accuracy than was a real-time quantitative polymerase chain reaction (qPCR)-based approach (P = 0.0041), and chest radiography (P = 0.0100). Even so, it is important that clinicians utilize a combination of laboratory and radiological testing where possible in order to ensure that this virus is reliably and quickly detected such that it may be treated and patients may be isolated in a timely fashion, thereby effectively curbing the further progression of this pandemic. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Zheng, Zhong","Yao, Zhixian","Wu, Ke","Zheng, Junhua"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462770","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jmv.26081","keywords":["chest radiography","computed tomography","coronavirus disease 2019","coronavirus pneumonia","diagnosis","polymerase chain reaction"],"topics":["Diagnosis"],"weight":1,"_version_":1668079521264304128,"score":182.911},{"pmid":32443459,"title":"Point-of-Care Diagnostic Tests for Detecting SARS-CoV-2 Antibodies: A Systematic Review and Meta-Analysis of Real-World Data.","text":["Point-of-Care Diagnostic Tests for Detecting SARS-CoV-2 Antibodies: A Systematic Review and Meta-Analysis of Real-World Data.","SARS-CoV-2 is responsible for a highly contagious infection, known as COVID-19. SARS-CoV-2 was discovered in late December 2019 and, since then, has become a global pandemic. Timely and accurate COVID-19 laboratory testing is an essential step in the management of the COVID-19 outbreak. To date, assays based on the reverse-transcription polymerase chain reaction (RT-PCR) in respiratory samples are the gold standard for COVID-19 diagnosis. Unfortunately, RT-PCR has several practical limitations. Consequently, alternative diagnostic methods are urgently required, both for alleviating the pressure on laboratories and healthcare facilities and for expanding testing capacity to enable large-scale screening and ensure a timely therapeutic intervention. To date, few studies have been conducted concerning the potential utilization of rapid testing for COVID-19, with some conflicting results. Therefore, the present systematic review and meta-analysis was undertaken to explore the feasibility of rapid diagnostic tests in the management of the COVID-19 outbreak. Based on ten studies, we computed a pooled sensitivity of 64.8% (95%CI 54.5-74.0), and specificity of 98.0% (95%CI 95.8-99.0), with high heterogeneity and risk of reporting bias. We can conclude that: (1) rapid diagnostic tests for COVID-19 are necessary, but should be adequately sensitive and specific; (2) few studies have been carried out to date; (3) the studies included are characterized by low numbers and low sample power, and (4) in light of these results, the use of available tests is currently questionable for clinical purposes and cannot substitute other more reliable molecular tests, such as assays based on RT-PCR.","J Clin Med","Ricco, Matteo","Ferraro, Pietro","Gualerzi, Giovanni","Ranzieri, Silvia","Henry, Brandon Michael","Said, Younes Ben","Pyatigorskaya, Natalia Valeryevna","Nevolina, Elena","Wu, Jianhong","Bragazzi, Nicola Luigi","Signorelli, Carlo","32443459"],"abstract":["SARS-CoV-2 is responsible for a highly contagious infection, known as COVID-19. SARS-CoV-2 was discovered in late December 2019 and, since then, has become a global pandemic. Timely and accurate COVID-19 laboratory testing is an essential step in the management of the COVID-19 outbreak. To date, assays based on the reverse-transcription polymerase chain reaction (RT-PCR) in respiratory samples are the gold standard for COVID-19 diagnosis. Unfortunately, RT-PCR has several practical limitations. Consequently, alternative diagnostic methods are urgently required, both for alleviating the pressure on laboratories and healthcare facilities and for expanding testing capacity to enable large-scale screening and ensure a timely therapeutic intervention. To date, few studies have been conducted concerning the potential utilization of rapid testing for COVID-19, with some conflicting results. Therefore, the present systematic review and meta-analysis was undertaken to explore the feasibility of rapid diagnostic tests in the management of the COVID-19 outbreak. Based on ten studies, we computed a pooled sensitivity of 64.8% (95%CI 54.5-74.0), and specificity of 98.0% (95%CI 95.8-99.0), with high heterogeneity and risk of reporting bias. We can conclude that: (1) rapid diagnostic tests for COVID-19 are necessary, but should be adequately sensitive and specific; (2) few studies have been carried out to date; (3) the studies included are characterized by low numbers and low sample power, and (4) in light of these results, the use of available tests is currently questionable for clinical purposes and cannot substitute other more reliable molecular tests, such as assays based on RT-PCR."],"journal":"J Clin Med","authors":["Ricco, Matteo","Ferraro, Pietro","Gualerzi, Giovanni","Ranzieri, Silvia","Henry, Brandon Michael","Said, Younes Ben","Pyatigorskaya, Natalia Valeryevna","Nevolina, Elena","Wu, Jianhong","Bragazzi, Nicola Luigi","Signorelli, Carlo"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32443459","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3390/jcm9051515","keywords":["covid-19","sars-cov-2","point-of-care diagnostics","rapid testing","real-world data","systematic review and meta-analysis"],"topics":["Diagnosis"],"weight":1,"_version_":1667600475779760129,"score":180.5808}]}